沙库巴曲缬沙坦联合琥珀酸美托洛尔缓释片治疗冠状动脉粥样硬化性心脏病并慢性心力衰竭的效果观察

目的 探究沙库巴曲缬沙坦联合琥珀酸美托洛尔缓释片治疗冠状动脉粥样硬化性心脏病（以下简称冠心病）并慢性心力衰竭患者的效果。方法 选取于2017年9月至2018年9月在河南科技大学第三附属医院和郑州市心血管病医院住院的冠心病并慢性心力衰竭患者为研究对象，按照入院顺序及年龄、病程、性别组间均衡的原则分为观察组（n=94）与对照组（n=93）。观察组给予沙库巴曲缬沙坦联合琥珀酸美托洛尔缓释片治疗，对照组给予琥珀酸美托洛尔缓释片治疗。两组患者均连续治疗6个月，对比两组治疗效果及治疗前后心功能指标：舒张早期最大充盈速度（maximum early filling speed，E）、左心室射血分数（ejection fraction，EF）、舒张晚期最大充盈速度（maximum filling speed in late diastole，A）、E/A、血管内皮功能

Effects of combined sacubitril/valsartan and metoprolol succinate sustained release tablets on patients who suffer from the coronary heart disease with chronic heart failure

Objective This paper was to explored the clinical efficacy of combined sacubitril/valsartan and metoprolol succinate sustained release tablets on patients who had the coronary heart disease with chronic heart failure. Methods This paper selected patients who suffered from the coronary heart disease with chronic heart failure in The Third Affiliated Hospital of Henan University of Science and Technology and Zhengzhou Cardiovascular Hospital from September 2017 to September 2018 as the samples. Based on intergroup equilibrium, the samples were divided into treatment group (n=94) and control group (n=93) uniformly by hospitalization date, age, disease course, and gender. Metoprolol succinate sustained release tablets were applied in control group, while sacubitril/valsartan and metoprolol succinate sustained release tablets were combined in treatment group. The therapy for patients in both group lasted for 6 months. This paper compared the clinical efficacy and cardiac function index:maximum early filling speed (E), left ventricular ejection fraction (EF), maximum filling speed in late diastole (A), E/A, vascular endothelial functionplasma endothelin (ET), calcitonin gene-related peptide (CGRP), nitric oxide (NO)], between two groups before and after the therapy. Results The clinical efficacy in treatment group was 93.62% which was significantly 78.49% higher than that in control group. After the therapy, E, EF, E/A, CGRP, NO in treatment group were higher than those in control group, while A and ET were lower in treatment group (P<0.05). Conclusion The therapy of combined sacubitril/valsartan and metoprolol succinate sustained release tablets had significant efficacy on coronary heart disease and heart failure by improving the cardiac function.